• The microbial contract biomanufacturing market is projected to be worth USD 9.3 billion by 2030

    The growing pipeline of biologics that can be produced in microbial systems, such as antibody fragments and plasmid-based therapies, is anticipated to offer lucrative opportunities to service providers serving this niche, but growing market segment

    For additional details, please visit
    https://www.rootsanalysis.com/reports/microbial-contract-biomanufacturing-market.html
    The microbial contract biomanufacturing market is projected to be worth USD 9.3 billion by 2030 The growing pipeline of biologics that can be produced in microbial systems, such as antibody fragments and plasmid-based therapies, is anticipated to offer lucrative opportunities to service providers serving this niche, but growing market segment For additional details, please visit https://www.rootsanalysis.com/reports/microbial-contract-biomanufacturing-market.html
    Microbial Contract Biomanufacturing Market, 2020-2030 | Market Size | Industry Analysis | 2030
    The microbial contract biomanufacturing market report features an extensive study of the current market landscape and future opportunities...
    WWW.ROOTSANALYSIS.COM
    0 Comments 0 Shares
  • The CAR-T therapies market is characterized by a healthy pipeline of promising therapies

    Given the success of approved CAR-T cell therapies, such as KYMRIAH®, YESCARTA®, TECARTUS® and BREYANZI®, this upcoming class of biologics are anticipated to carve out a significant share of the multi-billion dollar cancer immunotherapy market

    Roots Analysis has announced the addition of “CAR-T Cell Therapy Market (3rd Edition) by Target Indications (NHL, Multiple Myeloma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma, Hepatocellular Carcinoma and Others), Target Antigens (CD19, BCMA, CD19 / CD22, GPC3 and EGFR), Key Players and Key Geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World) – Industry Trends and Global Forecasts, 2021-2030” report to its list of offerings.

    Given their ability to selectively direct a cell mediated immune response against cancer cells and, thereby, offer prolonged periods of disease remission, several CAR-T cell therapies provide a promising therapeutic strategy for advanced stage cancers and are expected to achieve blockbuster status. With four approved products and many candidate therapies under evaluation for the treatment of multiple disease indications, the CAR-T cell therapy market is characterized by a healthy and growing pipeline. Further, with lucrative financial support and notable increase in partnerships, the CAR-T-cell therapies market is abuzz with activity.

    To order this 795+ page report, which features 165+ figures and 270+ tables, please visit https://www.rootsanalysis.com/reports/view_document/car-t-therapies-market/269.html

    Key Market Insights

    Over 755 CAR-T cell therapies are currently approved / under development
    Close to 40% of the aforementioned candidates are in preclinical and discovery stages, while more than 25% are being evaluated in clinical stages (phase I/II and above). Examples of late-stage clinical candidates include bb2121, CD123/CLL1 CAR-T CD19 CAR-T and LCAR-B38M CAR-T / JNJ-68284528.

    Currently, the focus is on developing product candidates to treat various types of cancers
    Over 95% of the products in the development pipeline are being evaluated for the treatment of hematological malignancies, including (in decreasing order of number of pipeline products) acute lymphoblastic leukemia, non-Hodgkin's lymphoma, multiple myeloma, and acute myeloid leukemia. Only 2% of current pipeline candidates are being developed for the treatment of non-oncological indications.

    Extensive efforts are underway to improve CAR constructs
    Majority of the product candidates in the clinical pipeline, including the four approved drug products, are based on second generation CARs. Further, a number of novel therapies armed with fourth generation CAR constructs, CAR-based products containing humanized scFv and bispecific CARs (CD19+CD20 or CD19+CD22 or CD19+CD30) are being evaluated worldwide.

    China is leading the product development efforts related to CAR-T cell therapies, in terms of number of active trials and supporting hospitals
    In the last 10 years, over half of the 410 clinical trials evaluating various types of CAR-T cell therapies, were registered in China. In addition, owning to a favorable clinical research environment, China is presently considered to be among the leading regions in the CAR-T cell therapy space, with close to 40 industry players and more than 100 non-industry players, including hospitals and universities, contributing to this field.

    Partnership activity within this domain has grown at a CAGR of 26%, between 2011 and 2020
    More than 220 agreements were inked related to CAR-T cell therapies, with the maximum activity being reported in 2018. Majority of partnership deals signed within this domain were R&D agreements (21%), technology licensing (20%) and product development and commercialization agreements (11%).

    Over USD 13 billion has been invested by both private and public investors, across more than 205 instances
    It is important to mention that, between 2013 and 2020, majority of the funding was acquired through venture capital rounds (37%), other equity financing elements (24%), grants (12%) and secondary offerings (12%).

    The market is anticipated to grow at a CAGR of over 28%, during the period 2021-2030
    Growth in this domain is anticipated to be primarily driven by encouraging clinical trial results and the recent success of the four approved CAR-T cell therapies. North America (primarily the US) and Europe are expected to capture over 75% of the market share by 2030, in terms of the sales-based revenues.

    To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/269/request-sample.html

    Key Questions Answered
     Who are the leading industry and non-industry players in this market?
     What are the prevalent R&D trends in CAR-T cell therapies domain?
     What are the key therapeutic areas for which CAR-T cell therapies are being / have been developed?
     What are the challenges faced by stakeholders in this industry?
     Which are the key geographies where extensive research on CAR-T cell therapies is being conducted?
     Who are the key investors in this domain?
     Who are the key opinion leaders / experts that can help in driving product development efforts in this field?
     What kind of partnership models are commonly adopted by industry stakeholders?
     What kind of contract manufacturing support is available for CAR-T cell therapies?
     What kind of promotional strategies are likely to be adopted for CAR-T cell therapies that are approved / commercialized in future?
     What are the factors that are likely to influence the evolution of this upcoming market?
     How is the current and future market opportunity likely to be distributed across key market segments?


    The USD 14 billion (by 2030) financial opportunity within the CAR-T cell therapy market has been analyzed across the following segments:

     Disease indication
     Non-Hodgkin lymphoma
     Multiple myeloma
     Chronic lymphocytic leukemia
     Acute lymphoblastic leukemia
     Follicular lymphoma
     Mantle cell lymphoma
     Hepatocellular carcinoma
     Colorectal cancer

     Target antigens
     CD19
     BCMA
     CD19, CD22
     GPC3
     EGFR

     Key Geographical Regions
     North America
     Europe
     Asia Pacific
     Latin America
     Middle East and North Africa
     Rest of the World

    The report features inputs from eminent industry stakeholders, according to whom CAR-T cell therapies are soon likely to witness increased adoption given their broad scope of applications in various advanced stage oncological disorders. The report includes detailed transcripts of discussions held with the following experts:
     Tim Oldham (Chief Executive Officer, Cell Therapies)
     Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics)
     Wei (William) Cao (Co-Founder, Chairman and Chief Executive Officer, Gracell Biotechnologies)
     Miguel Forte (Chief Operating Officer, TxCell)
     Adrian Bot (Vice President, Scientific Affairs, Kite Pharma)
     Vincent Brichard (Vice President, Immuno-Oncology, Celyad)
     Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)
     Aino Kalervo (Competitive Intelligence Manager, Strategy & Business Development, Theravectys)
     Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital)
     Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado)

    The research includes brief profiles, featuring an overview of the company, its financial information (if available), and a description of its product(s), highlighting type of therapy and current development status. Each company profile includes technology portfolio (if available), recent developments related to T-cell immunotherapies and manufacturing capabilities of the companies.
     Autolus
     bluebird bio
     CARsgen Therapeutics
     Celgene (A Bristol Myers Squibb Company)
     Cellectis
     Cellular Biomedicine Group
     Innovative Cellular Therapeutics
     Iovance Biotherapeutics
     Kite Pharma (A Gilead Sciences Company)
     Kuur Therapeutics
     Noile-Immune Biotech
     Novartis
     Shanghai Genechem
     Sinobioway Cell Therapy
     Takara Bio
     Ziopharm Oncology

    For additional details, please visit
    https://www.rootsanalysis.com/reports/view_document/car-t-therapies-market/269.html or email sales@rootsanalysis.com

    You may also be interested in the following titles:
    1. Global T-Cell Therapies Market (5th Edition), 2021 – 2030
    2. mRNA Therapeutics and Vaccines Market, 2020-2030
    3. Gene Therapies Market (4th Edition): Industry Trends and Global Forecasts, 2020-2030
    4. Oncolytic Virus Therapy Market: Pipeline Review, Developer Landscape and Competitive Insights, 2020-2030


    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com


    Contact:
    Ben Johnson
    +1 (415) 800 3415
    +44 (122) 391 1091
    Ben.johnson@rootsanalysis.com

    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Medium - https://medium.com/@RootsAnalysis
    Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora - https://rootsanalysisinsights.quora.com/
    The CAR-T therapies market is characterized by a healthy pipeline of promising therapies Given the success of approved CAR-T cell therapies, such as KYMRIAH®, YESCARTA®, TECARTUS® and BREYANZI®, this upcoming class of biologics are anticipated to carve out a significant share of the multi-billion dollar cancer immunotherapy market Roots Analysis has announced the addition of “CAR-T Cell Therapy Market (3rd Edition) by Target Indications (NHL, Multiple Myeloma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Follicular Lymphoma, Mantle Cell Lymphoma, Hepatocellular Carcinoma and Others), Target Antigens (CD19, BCMA, CD19 / CD22, GPC3 and EGFR), Key Players and Key Geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World) – Industry Trends and Global Forecasts, 2021-2030” report to its list of offerings. Given their ability to selectively direct a cell mediated immune response against cancer cells and, thereby, offer prolonged periods of disease remission, several CAR-T cell therapies provide a promising therapeutic strategy for advanced stage cancers and are expected to achieve blockbuster status. With four approved products and many candidate therapies under evaluation for the treatment of multiple disease indications, the CAR-T cell therapy market is characterized by a healthy and growing pipeline. Further, with lucrative financial support and notable increase in partnerships, the CAR-T-cell therapies market is abuzz with activity. To order this 795+ page report, which features 165+ figures and 270+ tables, please visit https://www.rootsanalysis.com/reports/view_document/car-t-therapies-market/269.html Key Market Insights Over 755 CAR-T cell therapies are currently approved / under development Close to 40% of the aforementioned candidates are in preclinical and discovery stages, while more than 25% are being evaluated in clinical stages (phase I/II and above). Examples of late-stage clinical candidates include bb2121, CD123/CLL1 CAR-T CD19 CAR-T and LCAR-B38M CAR-T / JNJ-68284528. Currently, the focus is on developing product candidates to treat various types of cancers Over 95% of the products in the development pipeline are being evaluated for the treatment of hematological malignancies, including (in decreasing order of number of pipeline products) acute lymphoblastic leukemia, non-Hodgkin's lymphoma, multiple myeloma, and acute myeloid leukemia. Only 2% of current pipeline candidates are being developed for the treatment of non-oncological indications. Extensive efforts are underway to improve CAR constructs Majority of the product candidates in the clinical pipeline, including the four approved drug products, are based on second generation CARs. Further, a number of novel therapies armed with fourth generation CAR constructs, CAR-based products containing humanized scFv and bispecific CARs (CD19+CD20 or CD19+CD22 or CD19+CD30) are being evaluated worldwide. China is leading the product development efforts related to CAR-T cell therapies, in terms of number of active trials and supporting hospitals In the last 10 years, over half of the 410 clinical trials evaluating various types of CAR-T cell therapies, were registered in China. In addition, owning to a favorable clinical research environment, China is presently considered to be among the leading regions in the CAR-T cell therapy space, with close to 40 industry players and more than 100 non-industry players, including hospitals and universities, contributing to this field. Partnership activity within this domain has grown at a CAGR of 26%, between 2011 and 2020 More than 220 agreements were inked related to CAR-T cell therapies, with the maximum activity being reported in 2018. Majority of partnership deals signed within this domain were R&D agreements (21%), technology licensing (20%) and product development and commercialization agreements (11%). Over USD 13 billion has been invested by both private and public investors, across more than 205 instances It is important to mention that, between 2013 and 2020, majority of the funding was acquired through venture capital rounds (37%), other equity financing elements (24%), grants (12%) and secondary offerings (12%). The market is anticipated to grow at a CAGR of over 28%, during the period 2021-2030 Growth in this domain is anticipated to be primarily driven by encouraging clinical trial results and the recent success of the four approved CAR-T cell therapies. North America (primarily the US) and Europe are expected to capture over 75% of the market share by 2030, in terms of the sales-based revenues. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/269/request-sample.html Key Questions Answered  Who are the leading industry and non-industry players in this market?  What are the prevalent R&D trends in CAR-T cell therapies domain?  What are the key therapeutic areas for which CAR-T cell therapies are being / have been developed?  What are the challenges faced by stakeholders in this industry?  Which are the key geographies where extensive research on CAR-T cell therapies is being conducted?  Who are the key investors in this domain?  Who are the key opinion leaders / experts that can help in driving product development efforts in this field?  What kind of partnership models are commonly adopted by industry stakeholders?  What kind of contract manufacturing support is available for CAR-T cell therapies?  What kind of promotional strategies are likely to be adopted for CAR-T cell therapies that are approved / commercialized in future?  What are the factors that are likely to influence the evolution of this upcoming market?  How is the current and future market opportunity likely to be distributed across key market segments? The USD 14 billion (by 2030) financial opportunity within the CAR-T cell therapy market has been analyzed across the following segments:  Disease indication  Non-Hodgkin lymphoma  Multiple myeloma  Chronic lymphocytic leukemia  Acute lymphoblastic leukemia  Follicular lymphoma  Mantle cell lymphoma  Hepatocellular carcinoma  Colorectal cancer  Target antigens  CD19  BCMA  CD19, CD22  GPC3  EGFR  Key Geographical Regions  North America  Europe  Asia Pacific  Latin America  Middle East and North Africa  Rest of the World The report features inputs from eminent industry stakeholders, according to whom CAR-T cell therapies are soon likely to witness increased adoption given their broad scope of applications in various advanced stage oncological disorders. The report includes detailed transcripts of discussions held with the following experts:  Tim Oldham (Chief Executive Officer, Cell Therapies)  Troels Jordansen (Chief Executive Officer, Glycostem Therapeutics)  Wei (William) Cao (Co-Founder, Chairman and Chief Executive Officer, Gracell Biotechnologies)  Miguel Forte (Chief Operating Officer, TxCell)  Adrian Bot (Vice President, Scientific Affairs, Kite Pharma)  Vincent Brichard (Vice President, Immuno-Oncology, Celyad)  Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)  Aino Kalervo (Competitive Intelligence Manager, Strategy & Business Development, Theravectys)  Xian-Bao Zhan (Professor of Medicine and Director, Department of Oncology, Changhai Hospital)  Enkhtsetseg Purev (Assistant Professor of Medicine, University of Colorado) The research includes brief profiles, featuring an overview of the company, its financial information (if available), and a description of its product(s), highlighting type of therapy and current development status. Each company profile includes technology portfolio (if available), recent developments related to T-cell immunotherapies and manufacturing capabilities of the companies.  Autolus  bluebird bio  CARsgen Therapeutics  Celgene (A Bristol Myers Squibb Company)  Cellectis  Cellular Biomedicine Group  Innovative Cellular Therapeutics  Iovance Biotherapeutics  Kite Pharma (A Gilead Sciences Company)  Kuur Therapeutics  Noile-Immune Biotech  Novartis  Shanghai Genechem  Sinobioway Cell Therapy  Takara Bio  Ziopharm Oncology For additional details, please visit https://www.rootsanalysis.com/reports/view_document/car-t-therapies-market/269.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Global T-Cell Therapies Market (5th Edition), 2021 – 2030 2. mRNA Therapeutics and Vaccines Market, 2020-2030 3. Gene Therapies Market (4th Edition): Industry Trends and Global Forecasts, 2020-2030 4. Oncolytic Virus Therapy Market: Pipeline Review, Developer Landscape and Competitive Insights, 2020-2030 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact: Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
    CAR-T Therapies Market (3rd Edition) | Industry Analysis | Market Size | 2030
    CAR-T Therapies market report features an extensive study of the current market landscape and future potential of the industry players
    WWW.ROOTSANALYSIS.COM
    0 Comments 0 Shares
  • The continuous and semi-continuous bioprocessing market

    The surge in demand for COVID-19 vaccines has presented lucrative opportunities for both innovators and contract service providers having continuous and semi-continuous manufacturing capabilities for biointensification

    London

    Roots Analysis has announced the addition of “Continuous and Semi-Continuous Bioprocessing Market, 2021 – 2030” report to its list of offerings.

    Given the growing pipeline of biological drugs, and the rising preference for such therapeutic interventions, the demand for cost-effective biomanufacturing processes has increased. As a result, several innovators and contract service providers are evaluating the potential of continuous and semi-continuous upstream and downstream bioprocessing technologies, owing to their various advantages.

    To order this 190+ page report, which features 60+ figures and 115+ tables, please visit this https://www.rootsanalysis.com/reports/continuous-and-semi-continuous-bioprocessing-market.html

    Key Market Insights

    Presently, more than 70 companies claim to have capabilities for continuous manufacturing of biologics
    Close to 45% of the continuous and semi-continuous bioprocessing companies are headquartered in Europe; further, around 20% of these companies have established their dedicated facilities in other geographical regions, such as North America and Asia-Pacific.

    Over 65% of the installed continuous upstream manufacturing capacity belongs to established players
    More than 40% of the global continuous upstream processing capacity is installed in Europe, followed by Asia-Pacific (33%). Further, close to 55% of the capacity belongs to the facilities owned by contract service providers.

    Continuous and semi-continuous bio-intensification approach has potential to save ~40% of the overall biopharmaceutical manufacturing cost
    By 2030, we expect that adoption of continuous and semi-continuous approach is likely to enable the net, annual cost savings of close to USD 50 billion.

    By 2030, the opportunity within the continuous and semi-continuous bioprocessing market is likely to be over USD 500 million
    Presently, the use of continuous and semi-continuous bio-intensification approach is largely restricted to the developed nations, and the majority of revenues from biologics manufactured via this approach are distributed between North America (~25%) and Europe (~40%). Once this process is adopted for the end-to-end manufacturing of biologics, estimates in the report suggest are likely to grow at even higher pace.

    To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/continuous-and-semi-continuous-bioprocessing-market.html

    Key Questions Answered
     Who are the leading contract manufacturers with expertise in continuous and semi-continuous bioprocessing?
     Who are the leading innovators / drug developers with expertise in continuous and semi-continuous bioprocessing?
     In which regions are majority of the continuous and semi-continuous bioprocessing facilities located?
     What is the likely cost saving potential of continuous and semi-continuous bioprocessing technology?
     What is the currently installed global capacity for continuous and semi-continuous bioprocessing?
     How is the current and future market opportunity likely to be distributed across key market segments?

    The USD 500+ million (by 2030) financial opportunity associated with continuous and semi-continuous bioprocessing services market has been analyzed across the following segments:
     Type of Manufacturer
     Innovator / Drug Developer
     Contract Service Provider

     Company Size
     Large
     Mid-sized
     Small

     Scale of Operation
     Preclinical / Clinical
     Commercial

     Stage of Bioprocess
     Upstream Bioprocessing
     Downstream Bioprocessing

     Geographical Regions
     North America
     Europe
     Asia-Pacific
     MENA
     Latin America and Rest of the World


    The report also features inputs from eminent industry stakeholders, according to whom, continuous and semi-continuous bioprocessing technologies are likely to witness a significant increase in the adoption rate in the near future, given their advantages over the traditional bioprocessing technologies. The report includes detailed transcripts of discussions held with the following experts:
     Jon Coffman (Senior Director of Bioprocess Technology and Engineering, AstraZeneca)
     Ehsan Mahdinia (Assistant Professor, Albany College of Pharmacy and Health Sciences)
     Himanshu Gadgil (Director and Chief Scientific Officer, Enzene Biosciences)


    The research includes profiles of key players (listed below), featuring a brief overview of the company, financial information (if available), details on its service portfolio, continuous and semi-continuous bioprocessing capabilities, scale of operation, stage of bioprocess, types of biologics manufactured, continuous and semi-continuous bioprocessing manufacturing facilities, recent developments and an informed future outlook.
     AGC Biologics
     Biogen
     Bristol-Myers Squibb
     Enzene Biosciences
     FUJIFLM Diosynth Biotechnologies
     Merck KGaA
     Novasep
     Sanofi Genzyme
     UCB Pharma
     WuXi Biologics


    For additional details, please visit
    https://www.rootsanalysis.com/reports/continuous-and-semi-continuous-bioprocessing-market.html or email sales@rootsanalysis.com


    You may also be interested in the following titles:
    1. Pharmaceutical Contract Research Services Market: Industry Trends and Global Forecasts, 2021-2030
    2. Lipid Contract Manufacturing Market: Industry Trends and Global Forecasts, 2021-2030
    3. Biologics Fill / Finish Services Market (2nd Edition): Industry Trends and Global Forecasts, 2021-2030
    4. Vaccine Contract Manufacturing Market (3rd Edition): Industry Trends and Global Forecasts, 2021-2030

    Contact Information
    Roots Analysis Private Limited
    Ben Johnson
    +1 (415) 800 3415
    ben.johnson@rootsanalysis.com
    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Medium - https://medium.com/@RootsAnalysis
    Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora - https://rootsanalysisinsights.quora.com/
    The continuous and semi-continuous bioprocessing market The surge in demand for COVID-19 vaccines has presented lucrative opportunities for both innovators and contract service providers having continuous and semi-continuous manufacturing capabilities for biointensification London Roots Analysis has announced the addition of “Continuous and Semi-Continuous Bioprocessing Market, 2021 – 2030” report to its list of offerings. Given the growing pipeline of biological drugs, and the rising preference for such therapeutic interventions, the demand for cost-effective biomanufacturing processes has increased. As a result, several innovators and contract service providers are evaluating the potential of continuous and semi-continuous upstream and downstream bioprocessing technologies, owing to their various advantages. To order this 190+ page report, which features 60+ figures and 115+ tables, please visit this https://www.rootsanalysis.com/reports/continuous-and-semi-continuous-bioprocessing-market.html Key Market Insights Presently, more than 70 companies claim to have capabilities for continuous manufacturing of biologics Close to 45% of the continuous and semi-continuous bioprocessing companies are headquartered in Europe; further, around 20% of these companies have established their dedicated facilities in other geographical regions, such as North America and Asia-Pacific. Over 65% of the installed continuous upstream manufacturing capacity belongs to established players More than 40% of the global continuous upstream processing capacity is installed in Europe, followed by Asia-Pacific (33%). Further, close to 55% of the capacity belongs to the facilities owned by contract service providers. Continuous and semi-continuous bio-intensification approach has potential to save ~40% of the overall biopharmaceutical manufacturing cost By 2030, we expect that adoption of continuous and semi-continuous approach is likely to enable the net, annual cost savings of close to USD 50 billion. By 2030, the opportunity within the continuous and semi-continuous bioprocessing market is likely to be over USD 500 million Presently, the use of continuous and semi-continuous bio-intensification approach is largely restricted to the developed nations, and the majority of revenues from biologics manufactured via this approach are distributed between North America (~25%) and Europe (~40%). Once this process is adopted for the end-to-end manufacturing of biologics, estimates in the report suggest are likely to grow at even higher pace. To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/continuous-and-semi-continuous-bioprocessing-market.html Key Questions Answered  Who are the leading contract manufacturers with expertise in continuous and semi-continuous bioprocessing?  Who are the leading innovators / drug developers with expertise in continuous and semi-continuous bioprocessing?  In which regions are majority of the continuous and semi-continuous bioprocessing facilities located?  What is the likely cost saving potential of continuous and semi-continuous bioprocessing technology?  What is the currently installed global capacity for continuous and semi-continuous bioprocessing?  How is the current and future market opportunity likely to be distributed across key market segments? The USD 500+ million (by 2030) financial opportunity associated with continuous and semi-continuous bioprocessing services market has been analyzed across the following segments:  Type of Manufacturer  Innovator / Drug Developer  Contract Service Provider  Company Size  Large  Mid-sized  Small  Scale of Operation  Preclinical / Clinical  Commercial  Stage of Bioprocess  Upstream Bioprocessing  Downstream Bioprocessing  Geographical Regions  North America  Europe  Asia-Pacific  MENA  Latin America and Rest of the World The report also features inputs from eminent industry stakeholders, according to whom, continuous and semi-continuous bioprocessing technologies are likely to witness a significant increase in the adoption rate in the near future, given their advantages over the traditional bioprocessing technologies. The report includes detailed transcripts of discussions held with the following experts:  Jon Coffman (Senior Director of Bioprocess Technology and Engineering, AstraZeneca)  Ehsan Mahdinia (Assistant Professor, Albany College of Pharmacy and Health Sciences)  Himanshu Gadgil (Director and Chief Scientific Officer, Enzene Biosciences) The research includes profiles of key players (listed below), featuring a brief overview of the company, financial information (if available), details on its service portfolio, continuous and semi-continuous bioprocessing capabilities, scale of operation, stage of bioprocess, types of biologics manufactured, continuous and semi-continuous bioprocessing manufacturing facilities, recent developments and an informed future outlook.  AGC Biologics  Biogen  Bristol-Myers Squibb  Enzene Biosciences  FUJIFLM Diosynth Biotechnologies  Merck KGaA  Novasep  Sanofi Genzyme  UCB Pharma  WuXi Biologics For additional details, please visit https://www.rootsanalysis.com/reports/continuous-and-semi-continuous-bioprocessing-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Pharmaceutical Contract Research Services Market: Industry Trends and Global Forecasts, 2021-2030 2. Lipid Contract Manufacturing Market: Industry Trends and Global Forecasts, 2021-2030 3. Biologics Fill / Finish Services Market (2nd Edition): Industry Trends and Global Forecasts, 2021-2030 4. Vaccine Contract Manufacturing Market (3rd Edition): Industry Trends and Global Forecasts, 2021-2030 Contact Information Roots Analysis Private Limited Ben Johnson +1 (415) 800 3415 ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
    Continuous and Semi-Continuous Bioprocessing | Market Size | Industry Analysis | 2030
    Continuous and Semi-Continuous Bioprocessing Market report features an extensive study of the current market landscape and future potential of the...
    WWW.ROOTSANALYSIS.COM
    0 Comments 0 Shares
  • The “Biopharmaceutical Contract Manufacturing Market (3rd edition), 2019 – 2030” report

    Over the years, the rising popularity of biologics has led to a paradigm shift in healthcare. In the last decade alone, the annual number of approvals of biopharmaceuticals, by the US FDA, have steadily risen.

    To order this 750+ page report, please visit this - https://rootsanalysis.com/reports/view_document/biopharma-contract-manufacturing-market-3rd-edition-2019-2030/250.html

    Key Inclusions
     A detailed review of the overall landscape of the biopharmaceutical contract manufacturing market, featuring a comprehensive list of active CMOs and detailed analysis of the manufacturing service providers based on a number of parameters, such as scale of operation (preclinical, clinical and commercial), type of biologics manufactured (peptides / proteins, antibodies, vaccines, cell therapies, gene therapies, antibody drug conjugates, vectors, biosimilars, nucleic acids and others), type of expression systems used (mammalian, microbial and others), year of establishment, employee size, geographical location of the CMO, number of manufacturing facilities, as well as the location of these facilities, GMP compliance, affiliations to regulatory agencies, type of bioreactors used (single-use bioreactors and stainless steel bioreactors), mode of operation of bioreactors (batch, fed-batch and perfusion) and bioprocessing capacity.
     Elaborate profiles of key players that have a diverse range of capabilities for the development, manufacturing and packaging of biologics. Each profile provides an overview of the company, its financial performance (if available), information related to its service portfolio, manufacturing facilities, and details on partnerships, recent developments (expansions), as well as a comprehensive future outlook.
     A detailed discussion on the key enablers in this domain, including certain niche product classes, such as antibody drug conjugates (ADCs), bispecific antibodies, cell therapies, gene therapies and viral vectors, which are likely to have a significant impact on the growth of the contract services market.
     A case study on the growing global biosimilars market, highlighting the opportunities for biopharmaceutical CMOs and CDMOs.
     A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.
     A discussion on challenges related to in-house manufacturing, featuring a brief overview of the various parameters that a drug / therapy developer may need to take into consideration while deciding whether to manufacture its products in-house or outsource.
     An analysis of the recent collaborations (signed since 2013) focused on the contract manufacturing of biologics; the analysis is based on various parameters, such as the year in which the agreement was signed, type of agreement, focus area and type of biologics.
     A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2013-2018, along with the geographical distribution of this activity. The analysis also depicts the relationship between important deal multiples based on the revenue, number of employees and experience of the acquired company.
     An analysis on the recent trends within biopharmaceutical contract manufacturing industry, highlighting various facility and capability expansions. In addition, it provides information on the technology advancements related to biomanufacturing.
     A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders (small-sized, mid-sized, large and very large CMOs / CDMOs) in the market, using data from both secondary and primary research. The study examines the distribution of global biopharmaceutical manufacturing capacity by scale of operation (preclinical / clinical, commercial), size of company (small-sized, mid-sized, large and very large), and geography (North America (the US and Canada), Europe (Italy, Germany, France, Spain, the UK and rest of Europe), Asia and Middle East (China, India, Japan, South Korea and rest of the Asia and Middle East), and rest of the world (including Australia).
     An informed estimate of the annual demand for biologics, taking into account the top 20 biologics, based on a various relevant parameter, such as target patient population, dosing frequency and dose strength of the abovementioned products.
     A discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall pharmaceutical industry.
     A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing CMO services to medical device developers.

    The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:
     Commonly Outsourced Business Operations
     Active Pharmaceutical Ingredients (API)
     Finished Dosage Formulations (FDF)
     Types of Expression System
     Mammalian
     Microbial
     Others
     Company Size
     Small
     Mid-Sized
     Large and Very Large
     Scale of Operation
     Preclinical
     Clinical
     Commercial
     Key Geographical Region
     North America
     Europe
     Asia-Pacific

    To request sample pages, please visit this - https://www.rootsanalysis.com/reports/250/request-sample.html

    Key Questions Answered
     Who are the key manufacturers (industry / non-industry) of cell-based therapies, across the world?
     What is the global demand for biologics-based therapies?
     What are the major recent developments (such as partnerships and expansions) in this industry?
     What kind of partnership models are commonly adopted by stakeholders in this domain?
     What is the current, installed contract manufacturing capacity for biologics?
     How is the current and future market opportunity likely to be distributed across key market segments?


    For more information, please click on the following link: https://www.rootsanalysis.com/reports/view_document/biopharmaceutical-contract-manufacturing-market/250.html


    You may also be interested in the following titles:
    1. Cell Therapy Manufacturing Market (3rd Edition), 2019-2030
    2. Antibody Contract Manufacturing Market, 2020-2030
    3. China Biopharmaceutical Contract Manufacturing Market, 2020-2030
    4. Peptide Therapeutics: Contract API Manufacturing Market, 2020-2030




    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

    Contact Information
    Roots Analysis Private Limited
    Ben Johnson
    +1 (415) 800 3415
    ben.johnson@rootsanalysis.com
    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Medium - https://medium.com/@RootsAnalysis
    Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora - https://rootsanalysisinsights.quora.com/
    The “Biopharmaceutical Contract Manufacturing Market (3rd edition), 2019 – 2030” report Over the years, the rising popularity of biologics has led to a paradigm shift in healthcare. In the last decade alone, the annual number of approvals of biopharmaceuticals, by the US FDA, have steadily risen. To order this 750+ page report, please visit this - https://rootsanalysis.com/reports/view_document/biopharma-contract-manufacturing-market-3rd-edition-2019-2030/250.html Key Inclusions  A detailed review of the overall landscape of the biopharmaceutical contract manufacturing market, featuring a comprehensive list of active CMOs and detailed analysis of the manufacturing service providers based on a number of parameters, such as scale of operation (preclinical, clinical and commercial), type of biologics manufactured (peptides / proteins, antibodies, vaccines, cell therapies, gene therapies, antibody drug conjugates, vectors, biosimilars, nucleic acids and others), type of expression systems used (mammalian, microbial and others), year of establishment, employee size, geographical location of the CMO, number of manufacturing facilities, as well as the location of these facilities, GMP compliance, affiliations to regulatory agencies, type of bioreactors used (single-use bioreactors and stainless steel bioreactors), mode of operation of bioreactors (batch, fed-batch and perfusion) and bioprocessing capacity.  Elaborate profiles of key players that have a diverse range of capabilities for the development, manufacturing and packaging of biologics. Each profile provides an overview of the company, its financial performance (if available), information related to its service portfolio, manufacturing facilities, and details on partnerships, recent developments (expansions), as well as a comprehensive future outlook.  A detailed discussion on the key enablers in this domain, including certain niche product classes, such as antibody drug conjugates (ADCs), bispecific antibodies, cell therapies, gene therapies and viral vectors, which are likely to have a significant impact on the growth of the contract services market.  A case study on the growing global biosimilars market, highlighting the opportunities for biopharmaceutical CMOs and CDMOs.  A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.  A discussion on challenges related to in-house manufacturing, featuring a brief overview of the various parameters that a drug / therapy developer may need to take into consideration while deciding whether to manufacture its products in-house or outsource.  An analysis of the recent collaborations (signed since 2013) focused on the contract manufacturing of biologics; the analysis is based on various parameters, such as the year in which the agreement was signed, type of agreement, focus area and type of biologics.  A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2013-2018, along with the geographical distribution of this activity. The analysis also depicts the relationship between important deal multiples based on the revenue, number of employees and experience of the acquired company.  An analysis on the recent trends within biopharmaceutical contract manufacturing industry, highlighting various facility and capability expansions. In addition, it provides information on the technology advancements related to biomanufacturing.  A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders (small-sized, mid-sized, large and very large CMOs / CDMOs) in the market, using data from both secondary and primary research. The study examines the distribution of global biopharmaceutical manufacturing capacity by scale of operation (preclinical / clinical, commercial), size of company (small-sized, mid-sized, large and very large), and geography (North America (the US and Canada), Europe (Italy, Germany, France, Spain, the UK and rest of Europe), Asia and Middle East (China, India, Japan, South Korea and rest of the Asia and Middle East), and rest of the world (including Australia).  An informed estimate of the annual demand for biologics, taking into account the top 20 biologics, based on a various relevant parameter, such as target patient population, dosing frequency and dose strength of the abovementioned products.  A discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall pharmaceutical industry.  A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing CMO services to medical device developers. The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:  Commonly Outsourced Business Operations  Active Pharmaceutical Ingredients (API)  Finished Dosage Formulations (FDF)  Types of Expression System  Mammalian  Microbial  Others  Company Size  Small  Mid-Sized  Large and Very Large  Scale of Operation  Preclinical  Clinical  Commercial  Key Geographical Region  North America  Europe  Asia-Pacific To request sample pages, please visit this - https://www.rootsanalysis.com/reports/250/request-sample.html Key Questions Answered  Who are the key manufacturers (industry / non-industry) of cell-based therapies, across the world?  What is the global demand for biologics-based therapies?  What are the major recent developments (such as partnerships and expansions) in this industry?  What kind of partnership models are commonly adopted by stakeholders in this domain?  What is the current, installed contract manufacturing capacity for biologics?  How is the current and future market opportunity likely to be distributed across key market segments? For more information, please click on the following link: https://www.rootsanalysis.com/reports/view_document/biopharmaceutical-contract-manufacturing-market/250.html You may also be interested in the following titles: 1. Cell Therapy Manufacturing Market (3rd Edition), 2019-2030 2. Antibody Contract Manufacturing Market, 2020-2030 3. China Biopharmaceutical Contract Manufacturing Market, 2020-2030 4. Peptide Therapeutics: Contract API Manufacturing Market, 2020-2030 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Ben Johnson +1 (415) 800 3415 ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
    0 Comments 0 Shares
  • China Biopharmaceutical Contract Manufacturing Market - Gaining Traction in the Pharmaceutical Industry

    The “China Biopharmaceutical Contract Manufacturing Market, 2020-2030” report features an extensive study of the current market landscape and future opportunities associated with the contract manufacturing of biopharmaceuticals in China. The study also features a detailed analysis of key drivers and trends related to this evolving domain.

    The current biopharmaceuticals market is characterized by high quality standards and a rapidly growing demand for novel and effective treatment options. It is, therefore, a technically challenging industry in which outsourcing has grown into a promising and prominent segment, especially for manufacturing and fill / finish operations. Outsourcing biopharmaceutical manufacturing operations to Asia is increasing at a rapid pace. In this, China has emerged as an attractive destination for outsourcing.

    To request a sample report: https://www.rootsanalysis.com/reports/313/request-sample.html

    Driven by rapid technological development, and an increasingly favorable policy landscape, the Chinese biopharmaceutical industry is projected to witness significant growth in the coming years. Considering the complications associated with the production and handling of biologic drugs, biopharmaceutical developers are always on the lookout for reliable contract service providers. As a result, CMOs / CDMOs in China have invested significant capital and other resources in order to develop the required scientific acumen, technical expertise and production capacity for biopharmaceuticals, over the past decade. As a result, several indigenous players currently claim to offer services and solutions at par with world-class biopharmaceutical CMOs and CDMOs. Further, several service provider companies based in developed regions, have also established wholly / partially owned facilities in this region. This strategic shift in location of manufacturing operations enables the aforementioned players to leverage the various region-specific advantages, related to biopharmaceutical manufacturing, which China has to offer.

    To order customize report: https://www.rootsanalysis.com/reports/china-biopharmaceutical-contract-manufacturing/request-customization.html

    Further, the recent approval of the market authorization holder (MAH) system on a national level, which was being run as a pilot program in several provinces since 2016, is a big achievement. This has led to an increase in outsourcing contracts to players based in China, which is further expected to decrease the idle capacity of CMOs, thereby reducing overall cost and increasing productivity; it is worth mentioning that, owing to rise in expansion initiatives carried out by biopharmaceutical CMOs in this region, over 50% of the biomanufacturing capacity is estimated to be idle / not utilized. In addition, as multiple biologics are likely to lose their patent exclusivity in the near future, the demand for biosimilars, especially monoclonal antibody (mAb) therapeutics, is expected to rise. Since these products cannot be marketed at exorbitant prices, firms often outsource their manufacturing operations to emerging regions, such as China, to enable savings; this is further likely to boost the growth of the Chinese biopharmaceutical CMOs market. Some the main advantages of outsourcing manufacturing operations to China-based CMOs / CDMOs are briefly described below:
     Availability of Skilled Labor: The country has a large pool of educated and capable individuals who are qualified to work in biopharmaceutical manufacturing plants. The recent increase in stringency of immigration policies, coupled to a scarcity of jobs in the developed regions, have cause many Chinese nationals to return to China. Such individuals, who have been trained in the West, are highly likely to be hired by Chinese firms. Further, a number of biopharmaceutical companies, such as Boehringer Ingelheim, GE Healthcare, Merck and Thermo Fisher Scientific, have either already established, or are planning to establish, manufacturing operations in China. This is anticipated to create several job opportunities for scientists and pharma workers in the region.
     Cost Advantages: Labor in developing regions, such as China, is much less expensive when compared to the US and Europe. This has garnered the interest of many multinational biopharmaceutical companies, especially those based in developed regions, causing them to offshore a lot of their production operations.
     Access to a Large Indigenous Marketplace: Product manufactured in China are granted easier access to the local market. On the other hand, regulations in China are actually prohibitive when it comes to foreign developers attempting to sell their offerings in the Chinese market. Considering the fact that the country is home to one of the largest populations, the region does offer a lucrative marketplace.
    Evolving Regulatory Framework and Government Support: The Chinese government is very supportive of local economic development, offering subsidies and incentives to indigenous initiatives. The introduction of the MAH guidelines, which provided special allowances for approval of drugs manufactured by contract organizations offered a significant boost to the contract services industry in the region.


    For more information, please click on the following link:
    https://www.rootsanalysis.com/reports/view_document/china-biopharmaceutical-contract-manufacturing/313.html

    You may also be interested in the following reports:
    1. Peptide Therapeutics
    2. Biopharmaceutical Excipient Manufacturing Market
    3. Single-use Sensors for Bioprocessing Market


    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

    Contact Information
    Roots Analysis Private Limited
    Ben Johnson
    +1 (415) 800 3415
    ben.johnson@rootsanalysis.com
    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Medium - https://medium.com/@RootsAnalysis
    Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora - https://rootsanalysisinsights.quora.com/
    China Biopharmaceutical Contract Manufacturing Market - Gaining Traction in the Pharmaceutical Industry The “China Biopharmaceutical Contract Manufacturing Market, 2020-2030” report features an extensive study of the current market landscape and future opportunities associated with the contract manufacturing of biopharmaceuticals in China. The study also features a detailed analysis of key drivers and trends related to this evolving domain. The current biopharmaceuticals market is characterized by high quality standards and a rapidly growing demand for novel and effective treatment options. It is, therefore, a technically challenging industry in which outsourcing has grown into a promising and prominent segment, especially for manufacturing and fill / finish operations. Outsourcing biopharmaceutical manufacturing operations to Asia is increasing at a rapid pace. In this, China has emerged as an attractive destination for outsourcing. To request a sample report: https://www.rootsanalysis.com/reports/313/request-sample.html Driven by rapid technological development, and an increasingly favorable policy landscape, the Chinese biopharmaceutical industry is projected to witness significant growth in the coming years. Considering the complications associated with the production and handling of biologic drugs, biopharmaceutical developers are always on the lookout for reliable contract service providers. As a result, CMOs / CDMOs in China have invested significant capital and other resources in order to develop the required scientific acumen, technical expertise and production capacity for biopharmaceuticals, over the past decade. As a result, several indigenous players currently claim to offer services and solutions at par with world-class biopharmaceutical CMOs and CDMOs. Further, several service provider companies based in developed regions, have also established wholly / partially owned facilities in this region. This strategic shift in location of manufacturing operations enables the aforementioned players to leverage the various region-specific advantages, related to biopharmaceutical manufacturing, which China has to offer. To order customize report: https://www.rootsanalysis.com/reports/china-biopharmaceutical-contract-manufacturing/request-customization.html Further, the recent approval of the market authorization holder (MAH) system on a national level, which was being run as a pilot program in several provinces since 2016, is a big achievement. This has led to an increase in outsourcing contracts to players based in China, which is further expected to decrease the idle capacity of CMOs, thereby reducing overall cost and increasing productivity; it is worth mentioning that, owing to rise in expansion initiatives carried out by biopharmaceutical CMOs in this region, over 50% of the biomanufacturing capacity is estimated to be idle / not utilized. In addition, as multiple biologics are likely to lose their patent exclusivity in the near future, the demand for biosimilars, especially monoclonal antibody (mAb) therapeutics, is expected to rise. Since these products cannot be marketed at exorbitant prices, firms often outsource their manufacturing operations to emerging regions, such as China, to enable savings; this is further likely to boost the growth of the Chinese biopharmaceutical CMOs market. Some the main advantages of outsourcing manufacturing operations to China-based CMOs / CDMOs are briefly described below:  Availability of Skilled Labor: The country has a large pool of educated and capable individuals who are qualified to work in biopharmaceutical manufacturing plants. The recent increase in stringency of immigration policies, coupled to a scarcity of jobs in the developed regions, have cause many Chinese nationals to return to China. Such individuals, who have been trained in the West, are highly likely to be hired by Chinese firms. Further, a number of biopharmaceutical companies, such as Boehringer Ingelheim, GE Healthcare, Merck and Thermo Fisher Scientific, have either already established, or are planning to establish, manufacturing operations in China. This is anticipated to create several job opportunities for scientists and pharma workers in the region.  Cost Advantages: Labor in developing regions, such as China, is much less expensive when compared to the US and Europe. This has garnered the interest of many multinational biopharmaceutical companies, especially those based in developed regions, causing them to offshore a lot of their production operations.  Access to a Large Indigenous Marketplace: Product manufactured in China are granted easier access to the local market. On the other hand, regulations in China are actually prohibitive when it comes to foreign developers attempting to sell their offerings in the Chinese market. Considering the fact that the country is home to one of the largest populations, the region does offer a lucrative marketplace. Evolving Regulatory Framework and Government Support: The Chinese government is very supportive of local economic development, offering subsidies and incentives to indigenous initiatives. The introduction of the MAH guidelines, which provided special allowances for approval of drugs manufactured by contract organizations offered a significant boost to the contract services industry in the region. For more information, please click on the following link: https://www.rootsanalysis.com/reports/view_document/china-biopharmaceutical-contract-manufacturing/313.html You may also be interested in the following reports: 1. Peptide Therapeutics 2. Biopharmaceutical Excipient Manufacturing Market 3. Single-use Sensors for Bioprocessing Market About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Ben Johnson +1 (415) 800 3415 ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
    Request Sample - China Biopharmaceutical Contract Manufacturing | Industry Analysis | Market Size | 2030
    Market research report on China biopharmaceutical contract manufacturing industry, with focus on current market landscape and 2030 market size
    WWW.ROOTSANALYSIS.COM
    0 Comments 0 Shares
  • With over 280 therapies under evaluation, the stem cell therapy market is estimated to be worth USD 8.5 Billion by 2030, claims Roots Analysis

    With multiple approved products, the field of stem cell therapies has gained substantial momentum over the last decade; several innovator companies are currently progressing their proprietary therapy candidates with cautious optimism. In fact, recent studies suggest that mesenchymal stem cells have the potential to end the Coronavirus (COVID-19) pandemic.

    Roots Analysis is pleased to announce the publication of its recent study, titled, “Global Stem Cells Market: Focus on Clinical Therapies, 2020–2030 (Based on Source (Allogeneic, Autologous); Origin (Adult, Embryonic); Type (Hematopoietic, Mesenchymal, Progenitor); Lineage (Amniotic Fluid, Adipose Tissue, Bone Marrow, Cardiosphere, Chondrocytes, Corneal Tissue, Cord Blood, Dental Pulp, Neural Tissue Placenta, Peripheral Blood, Stromal Cells); and Potency (Multipotent, Pluripotent))”.

    The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:
     A detailed assessment of the current market landscape of companies engaged in the development of stem cell therapies for treatment of wide range of clinical conditions
     Elaborate profiles of key industry players engaged in the development of stem cell therapies (shortlisted on the basis of the product portfolio).
     An insightful competitiveness analysis featuring a four-dimensional bubble chart, highlighting the key players in this domain.
     An assessment of over 20 commonly targeted therapeutic areas and details of stem cell-based therapies being developed to treat the same conditions.
     A detailed proprietary 2×2 representation that was developed to assess the current market scenario (in terms of existing competition and growth opportunities) across emerging and established market segments.
     An in-depth analysis of more than 1,500 grants that have been awarded to research institutes engaged in stem cell therapy-related projects, in the period between 2015 and 2019 (till November)
     A detailed clinical trial analysis on more than 540 completed, ongoing and planned studies of various stem cell therapies, highlighting prevalent trends across various relevant parameters.
     A review of the key aspects related to the manufacturing of stem cell therapies, including [A] a detailed discussion on processes and protocols, highlighting the need to outsource various aspects of stem cell therapy development and manufacturing operations, [B] an assessment of the current market landscape of contract manufacturers, providing information on stem cell-focused service providers, and [C] an insightful Harvey ball analysis to identify the key performance indicators / key considerations that industry stakeholders are likely to take into consideration while selecting a suitable CMO / CRO partner.
     A detailed market gap analysis in order to develop a realistic understanding of the demand and supply dynamics within this field, comparing both clinical and commercial capabilities of therapy developers and the availability and capabilities of contract manufacturers, across different geographies.
     An elaborate discussion on the various strategies that can be adopted by stem cell therapy developers across different stages of product development and commercialization.
     A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
     Source of Stem Cell
     Allogeneic
     Autologous

     Origin of Stem Cell
     Adult
     Embryonic

     Type of Stem Cell
     Hematopoietic
     Mesenchymal
     Progenitor
     Others

     Lineage of Stem Cell
     Adipose Tissue
     Bone Marrow
     Cord Blood
     Others

     Route of Administration
     Intraarticular
     Intracoronary
     Intramuscular
     Intramyocardial
     Intrathecal
     Intravenous
     Surgical Implantations
     Others

     Therapeutic Area
     Autoimmune / Inflammatory Disorder
     Cardiovascular Disorders
     Metabolic Disorder
     Musculoskeletal Disorders
     Oncological Disorders
     Neurological Disorders
     Ophthalmic Disorders
     Others

     End Users
     Ambulatory Surgery Centers
     Hospitals
     Specialty Clinics

     Key Geographical Regions
     North America
     Europe
     Asia-Pacific and Rest of the World

     Transcripts of interviews held with the following senior level representatives of stakeholder companies
     William L Rust (Founder and Chief Executive Officer, Seraxis)
     Xuejun Huang Parsons (Chief Executive Officer, Xcelthera)
     Michel Revel (Co-Founder and Chief Scientist, Kadimastem) and Galit Mazooz-Perlmuter (Director, Business Development, Kadimastem)
     Kikuo Yasui (Director and Chief Operating Officer, Heartseed)
     Gustav Steinhoff (Director and Chairman, Department of Cardiac Surgery, University of Rostock)
     Gilles Devillers (President, Bio Elpida)
     Fiona Bellot (Business Development Manager, Roslin Cell Therapies)
     David Mckenna (Professor and American Red Cross Chair in Transfusion Medicine, University of Minnesota)
     Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)
     Mathilde Girard (Department Leader, Cell Therapy Innovation and Development, YposKesi)

    Key companies covered in the report
     Anterogen
     Athersys
     CHABiotech
     Cytopeutics
     Hope Biosciences
     Japan Regenerative Medicine
     Lineage Cell Therapeutics
     Orchard Therapeutics
     Osiris Therapeutics
     Pluristem Therapeutics
     Promithera Biosciences
     Regenexx
     Stempeutics Research
     SCM Life Sciences
     TICEBA

    For more information please click on the following link:
    https://www.rootsanalysis.com/reports/view_document/stem-cells-market/296.html/

    Other Recent Offerings
    1. Stem Cell Therapy Contract Manufacturing Market, 2019-2030
    2. Antibody Drug Conjugates Market (5th Edition), 2019-2030
    3. Cell and Advanced Therapies Supply Chain Management Market, 2019-2030: Focus on Technological Solutions
    4. Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030

    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

    Contact Information
    Roots Analysis Private Limited
    Ben Johnson
    +1 (415) 800 3415
    ben.johnson@rootsanalysis.com
    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Medium - https://medium.com/@RootsAnalysis
    Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora - https://rootsanalysisinsights.quora.com/
    With over 280 therapies under evaluation, the stem cell therapy market is estimated to be worth USD 8.5 Billion by 2030, claims Roots Analysis With multiple approved products, the field of stem cell therapies has gained substantial momentum over the last decade; several innovator companies are currently progressing their proprietary therapy candidates with cautious optimism. In fact, recent studies suggest that mesenchymal stem cells have the potential to end the Coronavirus (COVID-19) pandemic. Roots Analysis is pleased to announce the publication of its recent study, titled, “Global Stem Cells Market: Focus on Clinical Therapies, 2020–2030 (Based on Source (Allogeneic, Autologous); Origin (Adult, Embryonic); Type (Hematopoietic, Mesenchymal, Progenitor); Lineage (Amniotic Fluid, Adipose Tissue, Bone Marrow, Cardiosphere, Chondrocytes, Corneal Tissue, Cord Blood, Dental Pulp, Neural Tissue Placenta, Peripheral Blood, Stromal Cells); and Potency (Multipotent, Pluripotent))”. The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:  A detailed assessment of the current market landscape of companies engaged in the development of stem cell therapies for treatment of wide range of clinical conditions  Elaborate profiles of key industry players engaged in the development of stem cell therapies (shortlisted on the basis of the product portfolio).  An insightful competitiveness analysis featuring a four-dimensional bubble chart, highlighting the key players in this domain.  An assessment of over 20 commonly targeted therapeutic areas and details of stem cell-based therapies being developed to treat the same conditions.  A detailed proprietary 2×2 representation that was developed to assess the current market scenario (in terms of existing competition and growth opportunities) across emerging and established market segments.  An in-depth analysis of more than 1,500 grants that have been awarded to research institutes engaged in stem cell therapy-related projects, in the period between 2015 and 2019 (till November)  A detailed clinical trial analysis on more than 540 completed, ongoing and planned studies of various stem cell therapies, highlighting prevalent trends across various relevant parameters.  A review of the key aspects related to the manufacturing of stem cell therapies, including [A] a detailed discussion on processes and protocols, highlighting the need to outsource various aspects of stem cell therapy development and manufacturing operations, [B] an assessment of the current market landscape of contract manufacturers, providing information on stem cell-focused service providers, and [C] an insightful Harvey ball analysis to identify the key performance indicators / key considerations that industry stakeholders are likely to take into consideration while selecting a suitable CMO / CRO partner.  A detailed market gap analysis in order to develop a realistic understanding of the demand and supply dynamics within this field, comparing both clinical and commercial capabilities of therapy developers and the availability and capabilities of contract manufacturers, across different geographies.  An elaborate discussion on the various strategies that can be adopted by stem cell therapy developers across different stages of product development and commercialization.  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)  Source of Stem Cell  Allogeneic  Autologous  Origin of Stem Cell  Adult  Embryonic  Type of Stem Cell  Hematopoietic  Mesenchymal  Progenitor  Others  Lineage of Stem Cell  Adipose Tissue  Bone Marrow  Cord Blood  Others  Route of Administration  Intraarticular  Intracoronary  Intramuscular  Intramyocardial  Intrathecal  Intravenous  Surgical Implantations  Others  Therapeutic Area  Autoimmune / Inflammatory Disorder  Cardiovascular Disorders  Metabolic Disorder  Musculoskeletal Disorders  Oncological Disorders  Neurological Disorders  Ophthalmic Disorders  Others  End Users  Ambulatory Surgery Centers  Hospitals  Specialty Clinics  Key Geographical Regions  North America  Europe  Asia-Pacific and Rest of the World  Transcripts of interviews held with the following senior level representatives of stakeholder companies  William L Rust (Founder and Chief Executive Officer, Seraxis)  Xuejun Huang Parsons (Chief Executive Officer, Xcelthera)  Michel Revel (Co-Founder and Chief Scientist, Kadimastem) and Galit Mazooz-Perlmuter (Director, Business Development, Kadimastem)  Kikuo Yasui (Director and Chief Operating Officer, Heartseed)  Gustav Steinhoff (Director and Chairman, Department of Cardiac Surgery, University of Rostock)  Gilles Devillers (President, Bio Elpida)  Fiona Bellot (Business Development Manager, Roslin Cell Therapies)  David Mckenna (Professor and American Red Cross Chair in Transfusion Medicine, University of Minnesota)  Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing)  Mathilde Girard (Department Leader, Cell Therapy Innovation and Development, YposKesi) Key companies covered in the report  Anterogen  Athersys  CHABiotech  Cytopeutics  Hope Biosciences  Japan Regenerative Medicine  Lineage Cell Therapeutics  Orchard Therapeutics  Osiris Therapeutics  Pluristem Therapeutics  Promithera Biosciences  Regenexx  Stempeutics Research  SCM Life Sciences  TICEBA For more information please click on the following link: https://www.rootsanalysis.com/reports/view_document/stem-cells-market/296.html/ Other Recent Offerings 1. Stem Cell Therapy Contract Manufacturing Market, 2019-2030 2. Antibody Drug Conjugates Market (5th Edition), 2019-2030 3. Cell and Advanced Therapies Supply Chain Management Market, 2019-2030: Focus on Technological Solutions 4. Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Ben Johnson +1 (415) 800 3415 ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
    Roots Analysis - Leaders in Pharmaceutical & Biotechnology Market Research
    Roots Analysis offers market research reports highlighting insightful opinions within the pharma, biotech and medical devices industry. With over 500 clients spread across the small pharma, large pharma, VC firms and academic institutes, our intellectual capital encompasses very niche / emerging market segments.
    WWW.ROOTSANALYSIS.COM
    0 Comments 0 Shares
  • The “Biopharmaceutical Contract Manufacturing Market (3rd edition), 2019 – 2030” report features an extensive study on the contract service providers within the biopharmaceutical industry

    To order this 750+ page report, please visit this - https://rootsanalysis.com/reports/view_document/biopharma-contract-manufacturing-market-3rd-edition-2019-2030/250.html

    Key Inclusions
     A detailed review of the overall landscape of the biopharmaceutical contract manufacturing market, featuring a comprehensive list of active CMOs and detailed analysis of the manufacturing service providers based on a number of parameters, such as scale of operation (preclinical, clinical and commercial), type of biologics manufactured (peptides / proteins, antibodies, vaccines, cell therapies, gene therapies, antibody drug conjugates, vectors, biosimilars, nucleic acids and others), type of expression systems used (mammalian, microbial and others), year of establishment, employee size, geographical location of the CMO, number of manufacturing facilities, as well as the location of these facilities, GMP compliance, affiliations to regulatory agencies, type of bioreactors used (single-use bioreactors and stainless steel bioreactors), mode of operation of bioreactors (batch, fed-batch and perfusion) and bioprocessing capacity.
     Elaborate profiles of key players that have a diverse range of capabilities for the development, manufacturing and packaging of biologics. Each profile provides an overview of the company, its financial performance (if available), information related to its service portfolio, manufacturing facilities, and details on partnerships, recent developments (expansions), as well as a comprehensive future outlook.
     A detailed discussion on the key enablers in this domain, including certain niche product classes, such as antibody drug conjugates (ADCs), bispecific antibodies, cell therapies, gene therapies and viral vectors, which are likely to have a significant impact on the growth of the contract services market.
     A case study on the growing global biosimilars market, highlighting the opportunities for biopharmaceutical CMOs and CDMOs.
     A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.
     A discussion on challenges related to in-house manufacturing, featuring a brief overview of the various parameters that a drug / therapy developer may need to take into consideration while deciding whether to manufacture its products in-house or outsource.
     An analysis of the recent collaborations (signed since 2013) focused on the contract manufacturing of biologics; the analysis is based on various parameters, such as the year in which the agreement was signed, type of agreement, focus area and type of biologics.
     A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2013-2018, along with the geographical distribution of this activity. The analysis also depicts the relationship between important deal multiples based on the revenue, number of employees and experience of the acquired company.
     An analysis on the recent trends within biopharmaceutical contract manufacturing industry, highlighting various facility and capability expansions. In addition, it provides information on the technology advancements related to biomanufacturing.
     A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders (small-sized, mid-sized, large and very large CMOs / CDMOs) in the market, using data from both secondary and primary research. The study examines the distribution of global biopharmaceutical manufacturing capacity by scale of operation (preclinical / clinical, commercial), size of company (small-sized, mid-sized, large and very large), and geography (North America (the US and Canada), Europe (Italy, Germany, France, Spain, the UK and rest of Europe), Asia and Middle East (China, India, Japan, South Korea and rest of the Asia and Middle East), and rest of the world (including Australia).
     An informed estimate of the annual demand for biologics, taking into account the top 20 biologics, based on a various relevant parameter, such as target patient population, dosing frequency and dose strength of the abovementioned products.
     A discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall pharmaceutical industry.
     A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing CMO services to medical device developers.

    The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:
     Commonly Outsourced Business Operations
     Active Pharmaceutical Ingredients (API)
     Finished Dosage Formulations (FDF)
     Types of Expression System
     Mammalian
     Microbial
     Others
     Company Size
     Small
     Mid-Sized
     Large and Very Large
     Scale of Operation
     Preclinical
     Clinical
     Commercial
     Key Geographical Region
     North America
     Europe
     Asia-Pacific

    To request sample pages, please visit this - https://www.rootsanalysis.com/reports/250/request-sample.html

    Key Questions Answered
     Who are the key manufacturers (industry / non-industry) of cell-based therapies, across the world?
     What is the global demand for biologics-based therapies?
     What are the major recent developments (such as partnerships and expansions) in this industry?
     What kind of partnership models are commonly adopted by stakeholders in this domain?
     What is the current, installed contract manufacturing capacity for biologics?
     How is the current and future market opportunity likely to be distributed across key market segments?


    For more information, please click on the following link: https://www.rootsanalysis.com/reports/view_document/biopharmaceutical-contract-manufacturing-market/250.html


    You may also be interested in the following titles:
    1. Cell Therapy Manufacturing Market (3rd Edition), 2019-2030
    2. Antibody Contract Manufacturing Market, 2020-2030
    3. China Biopharmaceutical Contract Manufacturing Market, 2020-2030
    4. Peptide Therapeutics: Contract API Manufacturing Market, 2020-2030




    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

    Contact Information
    Roots Analysis Private Limited
    Ben Johnson
    +1 (415) 800 3415
    ben.johnson@rootsanalysis.com
    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Medium - https://medium.com/@RootsAnalysis
    Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora - https://rootsanalysisinsights.quora.com/
    The “Biopharmaceutical Contract Manufacturing Market (3rd edition), 2019 – 2030” report features an extensive study on the contract service providers within the biopharmaceutical industry To order this 750+ page report, please visit this - https://rootsanalysis.com/reports/view_document/biopharma-contract-manufacturing-market-3rd-edition-2019-2030/250.html Key Inclusions  A detailed review of the overall landscape of the biopharmaceutical contract manufacturing market, featuring a comprehensive list of active CMOs and detailed analysis of the manufacturing service providers based on a number of parameters, such as scale of operation (preclinical, clinical and commercial), type of biologics manufactured (peptides / proteins, antibodies, vaccines, cell therapies, gene therapies, antibody drug conjugates, vectors, biosimilars, nucleic acids and others), type of expression systems used (mammalian, microbial and others), year of establishment, employee size, geographical location of the CMO, number of manufacturing facilities, as well as the location of these facilities, GMP compliance, affiliations to regulatory agencies, type of bioreactors used (single-use bioreactors and stainless steel bioreactors), mode of operation of bioreactors (batch, fed-batch and perfusion) and bioprocessing capacity.  Elaborate profiles of key players that have a diverse range of capabilities for the development, manufacturing and packaging of biologics. Each profile provides an overview of the company, its financial performance (if available), information related to its service portfolio, manufacturing facilities, and details on partnerships, recent developments (expansions), as well as a comprehensive future outlook.  A detailed discussion on the key enablers in this domain, including certain niche product classes, such as antibody drug conjugates (ADCs), bispecific antibodies, cell therapies, gene therapies and viral vectors, which are likely to have a significant impact on the growth of the contract services market.  A case study on the growing global biosimilars market, highlighting the opportunities for biopharmaceutical CMOs and CDMOs.  A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps involved in their respective manufacturing processes.  A discussion on challenges related to in-house manufacturing, featuring a brief overview of the various parameters that a drug / therapy developer may need to take into consideration while deciding whether to manufacture its products in-house or outsource.  An analysis of the recent collaborations (signed since 2013) focused on the contract manufacturing of biologics; the analysis is based on various parameters, such as the year in which the agreement was signed, type of agreement, focus area and type of biologics.  A detailed analysis of the various mergers and acquisitions that have taken place in this domain, highlighting the trend in the number of companies acquired between 2013-2018, along with the geographical distribution of this activity. The analysis also depicts the relationship between important deal multiples based on the revenue, number of employees and experience of the acquired company.  An analysis on the recent trends within biopharmaceutical contract manufacturing industry, highlighting various facility and capability expansions. In addition, it provides information on the technology advancements related to biomanufacturing.  A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders (small-sized, mid-sized, large and very large CMOs / CDMOs) in the market, using data from both secondary and primary research. The study examines the distribution of global biopharmaceutical manufacturing capacity by scale of operation (preclinical / clinical, commercial), size of company (small-sized, mid-sized, large and very large), and geography (North America (the US and Canada), Europe (Italy, Germany, France, Spain, the UK and rest of Europe), Asia and Middle East (China, India, Japan, South Korea and rest of the Asia and Middle East), and rest of the world (including Australia).  An informed estimate of the annual demand for biologics, taking into account the top 20 biologics, based on a various relevant parameter, such as target patient population, dosing frequency and dose strength of the abovementioned products.  A discussion on affiliated trends, key drivers and challenges, under a comprehensive SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall pharmaceutical industry.  A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing CMO services to medical device developers. The report also features the likely distribution of the current and forecasted opportunity across important market segments, mentioned below:  Commonly Outsourced Business Operations  Active Pharmaceutical Ingredients (API)  Finished Dosage Formulations (FDF)  Types of Expression System  Mammalian  Microbial  Others  Company Size  Small  Mid-Sized  Large and Very Large  Scale of Operation  Preclinical  Clinical  Commercial  Key Geographical Region  North America  Europe  Asia-Pacific To request sample pages, please visit this - https://www.rootsanalysis.com/reports/250/request-sample.html Key Questions Answered  Who are the key manufacturers (industry / non-industry) of cell-based therapies, across the world?  What is the global demand for biologics-based therapies?  What are the major recent developments (such as partnerships and expansions) in this industry?  What kind of partnership models are commonly adopted by stakeholders in this domain?  What is the current, installed contract manufacturing capacity for biologics?  How is the current and future market opportunity likely to be distributed across key market segments? For more information, please click on the following link: https://www.rootsanalysis.com/reports/view_document/biopharmaceutical-contract-manufacturing-market/250.html You may also be interested in the following titles: 1. Cell Therapy Manufacturing Market (3rd Edition), 2019-2030 2. Antibody Contract Manufacturing Market, 2020-2030 3. China Biopharmaceutical Contract Manufacturing Market, 2020-2030 4. Peptide Therapeutics: Contract API Manufacturing Market, 2020-2030 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Ben Johnson +1 (415) 800 3415 ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
    0 Comments 0 Shares
  • The cell therapy manufacturing market is estimated to be worth USD 14.5 billion in 2030, predicts Roots Analysis

    In order to meet the demand for cell therapy products and the growing need for effective therapeutic interventions, developers are actively outsourcing certain manufacturing operations, in addition to expanding their in-house capabilities

    Roots Analysis is pleased to announce the publication of its recent study, titled, “Cell Therapy Manufacturing Market (4th Edition), 2021-2030.”

    The report features an extensive study of the current market landscape and future opportunities associated with cell therapy manufacturing, along with information on both contract manufacturers, as well as developers having in-house production capabilities, offering in-depth analyses of the various business entities engaged in this domain, across key global regions. Amongst other elements, the report includes:
     A detailed review of the overall landscape of players engaged in the manufacturing of cell-based therapies, along with information on type of cell manufactured, source of cell, scale of operation, purpose of production, manufacturing capabilities / services offered, as well as location of headquarters and their respective manufacturing facilities.
     An analysis of the various expansion initiatives undertaken by service providers engaged in this domain in order to augment their respective cell therapy manufacturing capabilities.
     An analysis of the recent partnerships focused on the manufacturing of cell-based therapies, which have been established during the period 2016-2021.
     A review of the various cell therapy manufacturing initiatives undertaken by big pharma players engaged in this domain.
     Informed estimates of the annual commercial and clinical demand for cell therapies (in terms of number of patients).
     An estimate of the overall, installed capacity for the manufacturing of cell-based therapies.
     An in-depth analysis of cell therapy manufacturers using three versatile representations.
     A detailed analysis of various factors that are likely to influence the price of cell-based therapies.
     An elaborate discussion on the role of automation technologies in improving the current manufacturing methods.
     A qualitative analysis, highlighting the various factors that need to be taken into consideration by cell therapy developers, while deciding whether to manufacture their respective products in-house or engage the services of a CMO.
     A discussion on cell therapy manufacturing regulations across various geographies.
     Elaborate profiles of key players (industry and non-industry) that offer contract manufacturing services for cell-based therapies.
     A discussion on affiliated trends, key drivers and challenges, which are likely to impact the industry's evolution, under an elaborate SWOT framework.
     Insights generated in a market-wide survey, featuring inputs solicited from experts who are directly / indirectly involved in the development and / or manufacturing of cell-based therapies.
     A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
     Type of Cell Therapy
     T cell therapies
     Dendritic and tumor cell therapies
     NK cell therapies
     Stem cell therapies
     Other ATMPs
     Source of Cell
     Autologous
     Allogeneic
     Scale of Operation
     Clinical
     Commercial
     Purpose of Manufacturing
     In-house Manufacturing
     Contract Manufacturing
     Geographical Regions
     North America
     Europe
     Asia Pacific
     Rest of the World

    To request a sample copy / brochure of this report, please visit this
    https://www.rootsanalysis.com/reports/285/request-sample.html

    Key companies covered in the report
     BioNTech Innovative Manufacturing Services
     Cell and Gene Therapy Catapult
     Cell Therapies
     Center for Cell and Gene Therapy, Baylor College of Medicine
     Center for Cell Manufacturing Ireland, National University of Ireland
     Clinical Cell and Vaccine Production Facility, University of Pennsylvania
     Cognate BioServices
     FUJIFILM Cellular Dynamics
     Guy's and St. Thomas GMP Facility, Guy's Hospital
     KBI Biopharma
     Laboratory for Cell and Gene Medicine, Stanford University
     Lonza
     MEDINET
     Minaris Regenerative Medicine
     Molecular and Cellular Therapeutics, University of Minnesota
     Newcastle Cellular Therapies Facility, Newcastle University
     Nikon CeLL innovation
     Rayne Cell Therapy Suite, King's College London
     Roslin Cell Therapies
     Scottish National Blood Transfusion Service, Scottish Centre of Regenerative Medicine
     Sydney Cell and Gene Therapy
     Waisman Biomanufacturing
     WuXi AppTec

    For more information, please click on the following link:
    https://www.rootsanalysis.com/reports/view_document/cell-therapy-manufacturing/285.html

    Other Recent Offerings
    1. Biologics Fill / Finish Services Market (2nd Edition): Industry Trends and Global Forecasts, 2021-2030
    2. Vaccine Contract Manufacturing Market (3rd Edition): Industry Trends and Global Forecasts, 2021-2030
    3. TIL-based Therapies Market: Industry Trends and Global Forecasts, 2021-2030
    4. TCR-based Therapies Market: Industry Trends and Global Forecasts, 2021-2030
    5. Global T-Cell (CAR-T, TCR, and TIL) Therapies Market (5th Edition): Industry Trends and Global Forecasts, 2021-2030


    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

    Contact Information
    Roots Analysis Private Limited
    Ben Johnson
    +1 (415) 800 3415
    +44 (122) 391 1091
    Ben.johnson@rootsanalysis.com
    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Medium - https://medium.com/@RootsAnalysis
    Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora - https://rootsanalysisinsights.quora.com/
    The cell therapy manufacturing market is estimated to be worth USD 14.5 billion in 2030, predicts Roots Analysis In order to meet the demand for cell therapy products and the growing need for effective therapeutic interventions, developers are actively outsourcing certain manufacturing operations, in addition to expanding their in-house capabilities Roots Analysis is pleased to announce the publication of its recent study, titled, “Cell Therapy Manufacturing Market (4th Edition), 2021-2030.” The report features an extensive study of the current market landscape and future opportunities associated with cell therapy manufacturing, along with information on both contract manufacturers, as well as developers having in-house production capabilities, offering in-depth analyses of the various business entities engaged in this domain, across key global regions. Amongst other elements, the report includes:  A detailed review of the overall landscape of players engaged in the manufacturing of cell-based therapies, along with information on type of cell manufactured, source of cell, scale of operation, purpose of production, manufacturing capabilities / services offered, as well as location of headquarters and their respective manufacturing facilities.  An analysis of the various expansion initiatives undertaken by service providers engaged in this domain in order to augment their respective cell therapy manufacturing capabilities.  An analysis of the recent partnerships focused on the manufacturing of cell-based therapies, which have been established during the period 2016-2021.  A review of the various cell therapy manufacturing initiatives undertaken by big pharma players engaged in this domain.  Informed estimates of the annual commercial and clinical demand for cell therapies (in terms of number of patients).  An estimate of the overall, installed capacity for the manufacturing of cell-based therapies.  An in-depth analysis of cell therapy manufacturers using three versatile representations.  A detailed analysis of various factors that are likely to influence the price of cell-based therapies.  An elaborate discussion on the role of automation technologies in improving the current manufacturing methods.  A qualitative analysis, highlighting the various factors that need to be taken into consideration by cell therapy developers, while deciding whether to manufacture their respective products in-house or engage the services of a CMO.  A discussion on cell therapy manufacturing regulations across various geographies.  Elaborate profiles of key players (industry and non-industry) that offer contract manufacturing services for cell-based therapies.  A discussion on affiliated trends, key drivers and challenges, which are likely to impact the industry's evolution, under an elaborate SWOT framework.  Insights generated in a market-wide survey, featuring inputs solicited from experts who are directly / indirectly involved in the development and / or manufacturing of cell-based therapies.  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)  Type of Cell Therapy  T cell therapies  Dendritic and tumor cell therapies  NK cell therapies  Stem cell therapies  Other ATMPs  Source of Cell  Autologous  Allogeneic  Scale of Operation  Clinical  Commercial  Purpose of Manufacturing  In-house Manufacturing  Contract Manufacturing  Geographical Regions  North America  Europe  Asia Pacific  Rest of the World To request a sample copy / brochure of this report, please visit this https://www.rootsanalysis.com/reports/285/request-sample.html Key companies covered in the report  BioNTech Innovative Manufacturing Services  Cell and Gene Therapy Catapult  Cell Therapies  Center for Cell and Gene Therapy, Baylor College of Medicine  Center for Cell Manufacturing Ireland, National University of Ireland  Clinical Cell and Vaccine Production Facility, University of Pennsylvania  Cognate BioServices  FUJIFILM Cellular Dynamics  Guy's and St. Thomas GMP Facility, Guy's Hospital  KBI Biopharma  Laboratory for Cell and Gene Medicine, Stanford University  Lonza  MEDINET  Minaris Regenerative Medicine  Molecular and Cellular Therapeutics, University of Minnesota  Newcastle Cellular Therapies Facility, Newcastle University  Nikon CeLL innovation  Rayne Cell Therapy Suite, King's College London  Roslin Cell Therapies  Scottish National Blood Transfusion Service, Scottish Centre of Regenerative Medicine  Sydney Cell and Gene Therapy  Waisman Biomanufacturing  WuXi AppTec For more information, please click on the following link: https://www.rootsanalysis.com/reports/view_document/cell-therapy-manufacturing/285.html Other Recent Offerings 1. Biologics Fill / Finish Services Market (2nd Edition): Industry Trends and Global Forecasts, 2021-2030 2. Vaccine Contract Manufacturing Market (3rd Edition): Industry Trends and Global Forecasts, 2021-2030 3. TIL-based Therapies Market: Industry Trends and Global Forecasts, 2021-2030 4. TCR-based Therapies Market: Industry Trends and Global Forecasts, 2021-2030 5. Global T-Cell (CAR-T, TCR, and TIL) Therapies Market (5th Edition): Industry Trends and Global Forecasts, 2021-2030 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Ben Johnson +1 (415) 800 3415 +44 (122) 391 1091 Ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
    Request Sample - Cell Therapy Manufacturing Market (4th Edition) | Market Size | Industry Analysis | 2030
    Growing at an annualized rate of over 20%, the cell therapy manufacturing market is estimated to reach close to USD 10 Billion by 2030, claims Roots Analysis
    WWW.ROOTSANALYSIS.COM
    0 Comments 0 Shares
  • China Biopharmaceutical Contract Manufacturing Market - Gaining Traction in the Pharmaceutical Industry
    The “China Biopharmaceutical Contract Manufacturing Market, 2020-2030” report features an extensive study of the current market landscape and future opportunities associated with the contract manufacturing of biopharmaceuticals in China. The study also features a detailed analysis of key drivers and trends related to this evolving domain.

    The current biopharmaceuticals market is characterized by high quality standards and a rapidly growing demand for novel and effective treatment options. It is, therefore, a technically challenging industry in which outsourcing has grown into a promising and prominent segment, especially for manufacturing and fill / finish operations. Outsourcing biopharmaceutical manufacturing operations to Asia is increasing at a rapid pace. In this, China has emerged as an attractive destination for outsourcing.

    To request a sample report: https://www.rootsanalysis.com/reports/313/request-sample.html

    Driven by rapid technological development, and an increasingly favorable policy landscape, the Chinese biopharmaceutical industry is projected to witness significant growth in the coming years. Considering the complications associated with the production and handling of biologic drugs, biopharmaceutical developers are always on the lookout for reliable contract service providers. As a result, CMOs / CDMOs in China have invested significant capital and other resources in order to develop the required scientific acumen, technical expertise and production capacity for biopharmaceuticals, over the past decade. As a result, several indigenous players currently claim to offer services and solutions at par with world-class biopharmaceutical CMOs and CDMOs. Further, several service provider companies based in developed regions, have also established wholly / partially owned facilities in this region. This strategic shift in location of manufacturing operations enables the aforementioned players to leverage the various region-specific advantages, related to biopharmaceutical manufacturing, which China has to offer.

    To order customize report: https://www.rootsanalysis.com/reports/china-biopharmaceutical-contract-manufacturing/request-customization.html

    Further, the recent approval of the market authorization holder (MAH) system on a national level, which was being run as a pilot program in several provinces since 2016, is a big achievement. This has led to an increase in outsourcing contracts to players based in China, which is further expected to decrease the idle capacity of CMOs, thereby reducing overall cost and increasing productivity; it is worth mentioning that, owing to rise in expansion initiatives carried out by biopharmaceutical CMOs in this region, over 50% of the biomanufacturing capacity is estimated to be idle / not utilized. In addition, as multiple biologics are likely to lose their patent exclusivity in the near future, the demand for biosimilars, especially monoclonal antibody (mAb) therapeutics, is expected to rise. Since these products cannot be marketed at exorbitant prices, firms often outsource their manufacturing operations to emerging regions, such as China, to enable savings; this is further likely to boost the growth of the Chinese biopharmaceutical CMOs market. Some the main advantages of outsourcing manufacturing operations to China-based CMOs / CDMOs are briefly described below:
     Availability of Skilled Labor: The country has a large pool of educated and capable individuals who are qualified to work in biopharmaceutical manufacturing plants. The recent increase in stringency of immigration policies, coupled to a scarcity of jobs in the developed regions, have cause many Chinese nationals to return to China. Such individuals, who have been trained in the West, are highly likely to be hired by Chinese firms. Further, a number of biopharmaceutical companies, such as Boehringer Ingelheim, GE Healthcare, Merck and Thermo Fisher Scientific, have either already established, or are planning to establish, manufacturing operations in China. This is anticipated to create several job opportunities for scientists and pharma workers in the region.
     Cost Advantages: Labor in developing regions, such as China, is much less expensive when compared to the US and Europe. This has garnered the interest of many multinational biopharmaceutical companies, especially those based in developed regions, causing them to offshore a lot of their production operations.
     Access to a Large Indigenous Marketplace: Product manufactured in China are granted easier access to the local market. On the other hand, regulations in China are actually prohibitive when it comes to foreign developers attempting to sell their offerings in the Chinese market. Considering the fact that the country is home to one of the largest populations, the region does offer a lucrative marketplace.
    Evolving Regulatory Framework and Government Support: The Chinese government is very supportive of local economic development, offering subsidies and incentives to indigenous initiatives. The introduction of the MAH guidelines, which provided special allowances for approval of drugs manufactured by contract organizations offered a significant boost to the contract services industry in the region.


    For more information, please click on the following link:
    https://www.rootsanalysis.com/reports/view_document/china-biopharmaceutical-contract-manufacturing/313.html

    You may also be interested in the following reports:
    1. Peptide Therapeutics
    2. Biopharmaceutical Excipient Manufacturing Market
    3. Single-use Sensors for Bioprocessing Market


    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

    Contact Information
    Roots Analysis Private Limited
    Ben Johnson
    +1 (415) 800 3415
    ben.johnson@rootsanalysis.com
    Facebook - https://www.facebook.com/RootsAnalysis
    LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
    Twitter - https://twitter.com/RootsAnalysis
    Medium - https://medium.com/@RootsAnalysis
    Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora - https://rootsanalysisinsights.quora.com/
    China Biopharmaceutical Contract Manufacturing Market - Gaining Traction in the Pharmaceutical Industry The “China Biopharmaceutical Contract Manufacturing Market, 2020-2030” report features an extensive study of the current market landscape and future opportunities associated with the contract manufacturing of biopharmaceuticals in China. The study also features a detailed analysis of key drivers and trends related to this evolving domain. The current biopharmaceuticals market is characterized by high quality standards and a rapidly growing demand for novel and effective treatment options. It is, therefore, a technically challenging industry in which outsourcing has grown into a promising and prominent segment, especially for manufacturing and fill / finish operations. Outsourcing biopharmaceutical manufacturing operations to Asia is increasing at a rapid pace. In this, China has emerged as an attractive destination for outsourcing. To request a sample report: https://www.rootsanalysis.com/reports/313/request-sample.html Driven by rapid technological development, and an increasingly favorable policy landscape, the Chinese biopharmaceutical industry is projected to witness significant growth in the coming years. Considering the complications associated with the production and handling of biologic drugs, biopharmaceutical developers are always on the lookout for reliable contract service providers. As a result, CMOs / CDMOs in China have invested significant capital and other resources in order to develop the required scientific acumen, technical expertise and production capacity for biopharmaceuticals, over the past decade. As a result, several indigenous players currently claim to offer services and solutions at par with world-class biopharmaceutical CMOs and CDMOs. Further, several service provider companies based in developed regions, have also established wholly / partially owned facilities in this region. This strategic shift in location of manufacturing operations enables the aforementioned players to leverage the various region-specific advantages, related to biopharmaceutical manufacturing, which China has to offer. To order customize report: https://www.rootsanalysis.com/reports/china-biopharmaceutical-contract-manufacturing/request-customization.html Further, the recent approval of the market authorization holder (MAH) system on a national level, which was being run as a pilot program in several provinces since 2016, is a big achievement. This has led to an increase in outsourcing contracts to players based in China, which is further expected to decrease the idle capacity of CMOs, thereby reducing overall cost and increasing productivity; it is worth mentioning that, owing to rise in expansion initiatives carried out by biopharmaceutical CMOs in this region, over 50% of the biomanufacturing capacity is estimated to be idle / not utilized. In addition, as multiple biologics are likely to lose their patent exclusivity in the near future, the demand for biosimilars, especially monoclonal antibody (mAb) therapeutics, is expected to rise. Since these products cannot be marketed at exorbitant prices, firms often outsource their manufacturing operations to emerging regions, such as China, to enable savings; this is further likely to boost the growth of the Chinese biopharmaceutical CMOs market. Some the main advantages of outsourcing manufacturing operations to China-based CMOs / CDMOs are briefly described below:  Availability of Skilled Labor: The country has a large pool of educated and capable individuals who are qualified to work in biopharmaceutical manufacturing plants. The recent increase in stringency of immigration policies, coupled to a scarcity of jobs in the developed regions, have cause many Chinese nationals to return to China. Such individuals, who have been trained in the West, are highly likely to be hired by Chinese firms. Further, a number of biopharmaceutical companies, such as Boehringer Ingelheim, GE Healthcare, Merck and Thermo Fisher Scientific, have either already established, or are planning to establish, manufacturing operations in China. This is anticipated to create several job opportunities for scientists and pharma workers in the region.  Cost Advantages: Labor in developing regions, such as China, is much less expensive when compared to the US and Europe. This has garnered the interest of many multinational biopharmaceutical companies, especially those based in developed regions, causing them to offshore a lot of their production operations.  Access to a Large Indigenous Marketplace: Product manufactured in China are granted easier access to the local market. On the other hand, regulations in China are actually prohibitive when it comes to foreign developers attempting to sell their offerings in the Chinese market. Considering the fact that the country is home to one of the largest populations, the region does offer a lucrative marketplace. Evolving Regulatory Framework and Government Support: The Chinese government is very supportive of local economic development, offering subsidies and incentives to indigenous initiatives. The introduction of the MAH guidelines, which provided special allowances for approval of drugs manufactured by contract organizations offered a significant boost to the contract services industry in the region. For more information, please click on the following link: https://www.rootsanalysis.com/reports/view_document/china-biopharmaceutical-contract-manufacturing/313.html You may also be interested in the following reports: 1. Peptide Therapeutics 2. Biopharmaceutical Excipient Manufacturing Market 3. Single-use Sensors for Bioprocessing Market About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Information Roots Analysis Private Limited Ben Johnson +1 (415) 800 3415 ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis Medium - https://medium.com/@RootsAnalysis Pinterest - https://in.pinterest.com/RootsanalysisPin/_saved/ Quora - https://rootsanalysisinsights.quora.com/
    Request Sample - China Biopharmaceutical Contract Manufacturing | Industry Analysis | Market Size | 2030
    Market research report on China biopharmaceutical contract manufacturing industry, with focus on current market landscape and 2030 market size
    WWW.ROOTSANALYSIS.COM
    0 Comments 0 Shares
  • Biopharmaceutical Contract Biomanufacturing Market, (4th Edition), 2020-2030 by Roots Analysis
    Driven by several blockbuster products, a burgeoning pipeline and the need for dedicated expertise in the myriad of technical nuances associated with biomolecules, the biopharmaceutical contract manufacturing market has a lucrative future

    Roots Analysis is pleased to announce the publication of its recent study, titled, “Biopharmaceutical Contract Biomanufacturing Market, (4th Edition), 2020-2030.”

    The report features an extensive study on the contract service providers within the biopharmaceutical industry. The study features in-depth analyses, highlighting the capabilities of a diverse set of biopharmaceutical CMOs and contract development and manufacturing organizations (CDMOs). Amongst other elements, the report includes:
     A detailed review of the overall landscape of companies offering biopharmaceutical contract manufacturing services.
     A detailed landscape of the biopharmaceutical manufacturing facilities established across the key geographical regions.
     Elaborate profiles of key players that claim to have a diverse range of capabilities related to the development, manufacturing and packaging of biologics.
     A detailed discussion on the key enablers in this domain, including certain niche product classes, such as antibody drug conjugates (ADCs), bispecific antibodies, cell therapies, gene therapies and viral vectors.
     A case study on the growing global biosimilars market, highlighting the associated opportunities for biopharmaceutical CMOs and CDMOs.
     A case study comparing the key characteristics of small and large molecule drugs, along with details on the various steps involved in their respective manufacturing processes.
     A detailed discussion on the overview, benefits and challenges associated with in-house manufacturing.
     A qualitative analysis, highlighting the various factors that need to be taken into consideration by biopharmaceutical therapeutics / drug developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO.
     An analysis of the initiatives of big biopharma players engaged in this domain.
     An analysis of the recent collaborations, mergers and acquisitions and expansions that have been established in this domain, in the recent past.
     An analysis of the recent developments within the biopharmaceutical contract manufacturing industry.
     A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders engaged in this domain.
     An informed estimate of the annual demand for biologics based on several parameters.
     A discussion on affiliated trends, key drivers and challenges, under an elaborate SWOT framework.
     A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing contract manufacturing services to biopharmaceutical developers.
     A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
     Commonly outsourced business operations
     API
     FDF

    To order this 780+ page report, which features 300+ figures and 270+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/biopharmaceutical-contract-manufacturing-market/250.html



     Types of Expression Systems Used
     Mammalian
     Microbial
     Others

     Scale of Operation
     Preclinical / Clinical
     Commercial

     Company Size
     Small
     Mid-sized
     Large / Very Large

     Types of Biologics Manufactured
     Antibody Therapeutics
     Vaccines
     Cell Therapies
     Other Biologics

     Key Geographical Regions
     North America
     Europe
     Asia-Pacific
     Latin America
     Middle East and North Africa

    To request a sample copy / brochure of this report, please visit this - https://www.rootsanalysis.com/reports/250/request-sample.html


    Key companies covered in the report
     AGC Biologics
     Boehringer Ingelheim
     Catalent
     Cytiva (GE Healthcare)
     FUJIFILM Diosynth Biotechnologies
     KBI Biopharma
     Kemwell Biopharma
     Lonza
     Luina Bio
     Novasep
     Olon
     Patheon
     Piramal Pharma Solutions
     Takara Bio
     WuXi AppTec (WuXi Biologics)

    For additional details, please visit
    https://www.rootsanalysis.com/reports/view_document/biopharmaceutical-contract-manufacturing-market/250.html or email sales@rootsanalysis.com

    You may also be interested in the following titles:
    1. Vaccine Contract Manufacturing Market (3rd Edition), 2021-2030
    2. ADC Contract Manufacturing Market (4th Edition), 2020-2030
    3. Microbial Contract Manufacturing Market, 2020-2030
    About Roots Analysis
    Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com


    Contact Details
    Ben Johnson
    +1 (415) 800 3415
    ben.johnson@rootsanalysis.com

    Roots Analysis
    Web: https://www.rootsanalysis.com/
    LinkedIn: https://in.linkedin.com/company/roots-analysis
    Twitter: https://twitter.com/RootsAnalysis.com
    Medium: https://medium.com/@RootsAnalysis
    Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/
    Quora: https://rootsanalysisinsights.quora.com/
    Biopharmaceutical Contract Biomanufacturing Market, (4th Edition), 2020-2030 by Roots Analysis Driven by several blockbuster products, a burgeoning pipeline and the need for dedicated expertise in the myriad of technical nuances associated with biomolecules, the biopharmaceutical contract manufacturing market has a lucrative future Roots Analysis is pleased to announce the publication of its recent study, titled, “Biopharmaceutical Contract Biomanufacturing Market, (4th Edition), 2020-2030.” The report features an extensive study on the contract service providers within the biopharmaceutical industry. The study features in-depth analyses, highlighting the capabilities of a diverse set of biopharmaceutical CMOs and contract development and manufacturing organizations (CDMOs). Amongst other elements, the report includes:  A detailed review of the overall landscape of companies offering biopharmaceutical contract manufacturing services.  A detailed landscape of the biopharmaceutical manufacturing facilities established across the key geographical regions.  Elaborate profiles of key players that claim to have a diverse range of capabilities related to the development, manufacturing and packaging of biologics.  A detailed discussion on the key enablers in this domain, including certain niche product classes, such as antibody drug conjugates (ADCs), bispecific antibodies, cell therapies, gene therapies and viral vectors.  A case study on the growing global biosimilars market, highlighting the associated opportunities for biopharmaceutical CMOs and CDMOs.  A case study comparing the key characteristics of small and large molecule drugs, along with details on the various steps involved in their respective manufacturing processes.  A detailed discussion on the overview, benefits and challenges associated with in-house manufacturing.  A qualitative analysis, highlighting the various factors that need to be taken into consideration by biopharmaceutical therapeutics / drug developers while deciding whether to manufacture their respective products in-house or engage the services of a CMO.  An analysis of the initiatives of big biopharma players engaged in this domain.  An analysis of the recent collaborations, mergers and acquisitions and expansions that have been established in this domain, in the recent past.  An analysis of the recent developments within the biopharmaceutical contract manufacturing industry.  A detailed capacity analysis, taking into consideration the individual development and manufacturing capacities of various stakeholders engaged in this domain.  An informed estimate of the annual demand for biologics based on several parameters.  A discussion on affiliated trends, key drivers and challenges, under an elaborate SWOT framework.  A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing contract manufacturing services to biopharmaceutical developers.  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)  Commonly outsourced business operations  API  FDF To order this 780+ page report, which features 300+ figures and 270+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/biopharmaceutical-contract-manufacturing-market/250.html  Types of Expression Systems Used  Mammalian  Microbial  Others  Scale of Operation  Preclinical / Clinical  Commercial  Company Size  Small  Mid-sized  Large / Very Large  Types of Biologics Manufactured  Antibody Therapeutics  Vaccines  Cell Therapies  Other Biologics  Key Geographical Regions  North America  Europe  Asia-Pacific  Latin America  Middle East and North Africa To request a sample copy / brochure of this report, please visit this - https://www.rootsanalysis.com/reports/250/request-sample.html Key companies covered in the report  AGC Biologics  Boehringer Ingelheim  Catalent  Cytiva (GE Healthcare)  FUJIFILM Diosynth Biotechnologies  KBI Biopharma  Kemwell Biopharma  Lonza  Luina Bio  Novasep  Olon  Patheon  Piramal Pharma Solutions  Takara Bio  WuXi AppTec (WuXi Biologics) For additional details, please visit https://www.rootsanalysis.com/reports/view_document/biopharmaceutical-contract-manufacturing-market/250.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Vaccine Contract Manufacturing Market (3rd Edition), 2021-2030 2. ADC Contract Manufacturing Market (4th Edition), 2020-2030 3. Microbial Contract Manufacturing Market, 2020-2030 About Roots Analysis Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com Contact Details Ben Johnson +1 (415) 800 3415 ben.johnson@rootsanalysis.com Roots Analysis Web: https://www.rootsanalysis.com/ LinkedIn: https://in.linkedin.com/company/roots-analysis Twitter: https://twitter.com/RootsAnalysis.com Medium: https://medium.com/@RootsAnalysis Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/ Quora: https://rootsanalysisinsights.quora.com/
    Biopharmaceutical Contract Manufacturing Market (4th Edition) | Industry Analysis | Market Size | 2030
    With a current capacity utilization of ~70%, the biopharma contract manufacturing (CMO) market is equiped to handle the growing demand for biologics
    WWW.ROOTSANALYSIS.COM
    0 Comments 0 Shares

No results to show

No results to show

No results to show

No results to show

Sponsored